Get the Stockscreener App
2.09
1.42%
-0.03
After Hours:
2.14
0.05
+2.39%
Perspective Therapeutics Inc stock is traded at $2.09, with a volume of 1.92M.
It is down -1.42% in the last 24 hours and down -32.80% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$2.12
Open:
$2.12
24h Volume:
1.92M
Relative Volume:
1.41
Market Cap:
$155.37M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-12.18
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+0.48%
1M Performance:
-32.80%
6M Performance:
-15.04%
1Y Performance:
-30.33%
1-Day Range:
$1.955
$2.1692
1-Week Range:
$1.955
$2.54
52-Week Range:
$1.60
$5.3881
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.09 | 157.60M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics Inc Stock Analysis and ForecastMonthly Performance Summary & Bull Bear Market Updates - earlytimes.in
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - Nasdaq
Perspective Therapeutics (CATX): UBS Maintains Rating but Lowers Price Target | CATX Stock News - GuruFocus
UBS lowers Perspective Therapeutics stock price target on competition concerns - Investing.com Nigeria
How Perspective Therapeutics Inc. stock reacts to stronger dollarBull Run & Stock Timing and Entry Methods - newser.com
Will Perspective Therapeutics Inc. stock outperform global peersQuarterly Market Summary & Consistent Growth Stock Picks - newser.com
Why Perspective Therapeutics Inc. stock could rally stronglyEarnings Summary Report & Risk Managed Investment Signals - newser.com
Is Perspective Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Is Perspective Therapeutics Inc. stock attractive post correction2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
What machine learning models say about Perspective Therapeutics Inc.Weekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com
How geopolitical risks impact Perspective Therapeutics Inc. (AAJ0) stockJuly 2025 Summary & Daily Technical Stock Forecast Reports - newser.com
Perspective Therapeutics to Participate in Upcoming December Conferences - The Manila Times
Perspective Therapeutics, Inc. Announces Participation in Upcoming Healthcare Conferences for Investor Engagement - Quiver Quantitative
Perspective (CATX) to meet investors at Piper Sandler and Evercore healthcare events - Stock Titan
Can Perspective Therapeutics Inc. stock attract ESG investmentsWall Street Watch & Verified Momentum Stock Watchlist - newser.com
Will Perspective Therapeutics Inc. stock beat value stocks2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
Will Perspective Therapeutics Inc. (AAJ0) stock keep high P E multiplesTrade Signal Summary & High Accuracy Trade Alerts - newser.com
Will Perspective Therapeutics Inc. stock announce special dividendWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
How Perspective Therapeutics Inc. stock reacts to inflationary pressures2025 Growth vs Value & Long-Term Growth Plans - newser.com
Why Perspective Therapeutics Inc. (AAJ0) stock is listed among top recommendations2025 Market Trends & Long Hold Capital Preservation Plans - newser.com
Can Perspective Therapeutics Inc. stock hit record highs againTrade Entry Report & Fast Entry High Yield Stock Tips - newser.com
Can Perspective Therapeutics Inc. recover in the next quarterWeekly Gains Summary & Weekly Watchlist for Consistent Profits - newser.com
Is Perspective Therapeutics Inc. (AAJ0) stock a defensive play amid uncertaintyEarnings Miss & Long-Term Growth Plans - newser.com
Key metrics from Perspective Therapeutics Inc.’s quarterly dataTrade Risk Summary & Long-Term Safe Investment Plans - newser.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.84%
Cap:
|
Volume (24h):